MarzNC
Well-known member
- Joined
- Jul 18, 2020
Hopefully a last post about ivermectin. Feel free to ignore. Ivermectin may be worth investigating as part of combination treatment for mild/moderate cases of COVID-19, but the folks pushing it hard in social media and claiming they are being censored right now are not trustworthy in my opinion.
Found that a key research article touted on the website of the proponents of a specific ivermectin treatment approach was rejected in March 2021 by an international journal. Essentially it didn't pass the peer review process. Frontiers is a non-profit founded by a neuroscientists in Switzerland in 2007. It stays in business because in 2021 "Frontiers becomes financially self-sustainable with the Article Processing Charges business model." Not exactly in the same class as the New England Journal of Medicine or the Lancet.
April 2021, The Conversation
Ivermectin: why a potential COVID treatment isn’t recommended for use
March 2, 2021, The Scientist
Frontiers Removes Controversial Ivermectin Paper Pre-Publication
March 2, 2021, Frontiers
"
Article rejection: Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.
Dr. Frederick Fenter, Chief Executive Editor of Frontiers:
“Regardless of the publication stage or subject of a manuscript, if the integrity of an article is called into question, our policy is to investigate. Upon further scrutiny by our Research Integrity team about the objectivity of this paper during the provisional acceptance phase, it was revealed that the article made a series of strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups. Further, the authors promoted their own specific ivermectin-based treatment which is inappropriate for a review article and against our editorial policies.
“In our view, this paper does not offer an objective nor balanced scientific contribution to the evaluation of ivermectin as a potential treatment for COVID-19. Frontiers’ has published more than 2,000 rigorously peer-reviewed articles on COVID-19 since the pandemic erupted via our Coronavirus Knowledge Hub, and we are acutely aware of just how critical high-quality, objective research in this area is at this time. Frontiers takes no position on the efficacy of ivermectin as a treatment of patients with COVID-19, however, we do take a very firm stance against unbalanced or unsupported scientific conclusions.
. . ."
Found that a key research article touted on the website of the proponents of a specific ivermectin treatment approach was rejected in March 2021 by an international journal. Essentially it didn't pass the peer review process. Frontiers is a non-profit founded by a neuroscientists in Switzerland in 2007. It stays in business because in 2021 "Frontiers becomes financially self-sustainable with the Article Processing Charges business model." Not exactly in the same class as the New England Journal of Medicine or the Lancet.
April 2021, The Conversation
Ivermectin: why a potential COVID treatment isn’t recommended for use
Ivermectin: why a potential COVID treatment isn’t recommended for use
The antiparasitic drug was thought to be a potential treatment for COVID-19, but there isn’t sufficient evidence to recommend its use, despite widespread support online.
theconversation.com
March 2, 2021, The Scientist
Frontiers Removes Controversial Ivermectin Paper Pre-Publication
Frontiers Removes Controversial Ivermectin Paper Pre-Publication
A review article containing contested claims about the tropical medicine drug as a COVID-19 treatment was listed as "provisionally accepted" on the journal's website before being removed this week.
www.the-scientist.com
March 2, 2021, Frontiers
2 March 2021 – Media statement
Article rejection: Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Dr. Frederick Fenter,
blog.frontiersin.org
Article rejection: Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.
Dr. Frederick Fenter, Chief Executive Editor of Frontiers:
“Regardless of the publication stage or subject of a manuscript, if the integrity of an article is called into question, our policy is to investigate. Upon further scrutiny by our Research Integrity team about the objectivity of this paper during the provisional acceptance phase, it was revealed that the article made a series of strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups. Further, the authors promoted their own specific ivermectin-based treatment which is inappropriate for a review article and against our editorial policies.
“In our view, this paper does not offer an objective nor balanced scientific contribution to the evaluation of ivermectin as a potential treatment for COVID-19. Frontiers’ has published more than 2,000 rigorously peer-reviewed articles on COVID-19 since the pandemic erupted via our Coronavirus Knowledge Hub, and we are acutely aware of just how critical high-quality, objective research in this area is at this time. Frontiers takes no position on the efficacy of ivermectin as a treatment of patients with COVID-19, however, we do take a very firm stance against unbalanced or unsupported scientific conclusions.
. . ."